Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658632 · ClinicalTrials.gov registry record · Phase 3
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,397
- Enrollment target
NCT00658632 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 1,397 participants.
The verdict
NCT00658632, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,397 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
Interventions
- DRUG Esomeprazole
- DRUG Rabeprazole sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,397 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658632
The ClinicalTrials.gov registry entry for NCT00658632 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,397 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Esomeprazole is the first listed.
NCT00658632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658632 about?
NCT00658632 is a clinical study titled "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)". The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
What is the current status of trial NCT00658632?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,397 participants. The study started on 2008-02. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00658632?
The interventions under investigation include: Esomeprazole (DRUG), Rabeprazole sodium (DRUG).
Who is sponsoring clinical trial NCT00658632?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.